CMV-TCR-T cells / BriSTAR Immunotech - LARVOL DELTA

CMV-TCR-T Cells for CM Virus Infection After HSCT (clinicaltrials.gov) - P1 | N=17 | Completed | Sponsor: Hebei Yanda Ludaopei Hospital | Recruiting ➔ Completed

Trial completion • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease

Efficacy of pp65-specific TCR-T cell therapy in treating cytomegalovirus infection after hematopoietic stem cell transplantation. (PubMed, Am J Hematol) - P1 | "In a phase I clinical trial (NCT04153279), CMV TCR-T cells were applied to treat patients with CMV reactivation after HSCT...Among them, 2 patients have survived for more than one year. This study demonstrates the great potential in the treatment and prevention of CMV infection following HSCT or other organ transplantation."

Journal • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease • Inflammation • Oncology • Transplantation

CMV-TCR-T Cells for CM Virus Infection After HSCT (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Hebei Yanda Ludaopei Hospital | Trial completion date: Jan 2022 ➔ Dec 2022 | Trial primary completion date: Oct 2021 ➔ Oct 2022

Trial completion date • Trial primary completion date • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease